Cognition Therapeutics Presents Complete EEG Findings From SEQUEL Study Of CT1812 In Mild-To-Moderate Alzheimer's Disease At CTAD
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced complete EEG findings from the Phase 2 SEQUEL study on CT1812, a treatment for mild-to-moderate Alzheimer's disease. The study showed that CT1812-treated participants exhibited a statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters. The positive changes occurred after only a short treatment interval, providing optimism that CT1812 is altering underlying Alzheimer's disease processes.
October 24, 2023 | 8:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cognition Therapeutics' Phase 2 SEQUEL study shows promising results for CT1812 in treating Alzheimer's disease. This could potentially boost the company's stock as it indicates progress in their drug development.
The positive results from the Phase 2 SEQUEL study indicate that Cognition Therapeutics is making progress in the development of CT1812, a treatment for Alzheimer's disease. This could potentially attract more investors, leading to an increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100